{
  "nodes": [
    {
      "id": "node_001",
      "content": "EGFR S768I, L861Q, and/or G719X mutations",
      "parent_ids": [],
      "children_ids": [
        "node_002",
        "node_003"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "nn"
      ]
    },
    {
      "id": "node_002",
      "content": "EGFR mutation discovered prior to first-line systemic therapy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_004",
        "node_005",
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_003",
      "content": "EGFR mutation discovered during first-line systemic therapy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_013"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_004",
      "content": "Preferred: Afatinib",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_007"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss"
      ]
    },
    {
      "id": "node_005",
      "content": "Preferred: Osimertinib",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_009"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss"
      ]
    },
    {
      "id": "node_006",
      "content": "Other Recommended: Dacomitinib or Erlotinib or Gefitinib",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_011"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss"
      ]
    },
    {
      "id": "node_007",
      "content": "Progression",
      "parent_ids": [
        "node_004"
      ],
      "children_ids": [
        "node_008"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_008",
      "content": "Subsequent Therapy (NSCL-23)",
      "parent_ids": [
        "node_007"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-23"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_009",
      "content": "Progression",
      "parent_ids": [
        "node_005"
      ],
      "children_ids": [
        "node_010"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_010",
      "content": "Subsequent Therapy (NSCL-22)",
      "parent_ids": [
        "node_009"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-22"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_011",
      "content": "Progression",
      "parent_ids": [
        "node_006"
      ],
      "children_ids": [
        "node_012"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_012",
      "content": "Subsequent Therapy (NSCL-23)",
      "parent_ids": [
        "node_011"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-23"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_013",
      "content": "Interrupt current therapy and start",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_014",
        "node_015",
        "node_016"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ww",
        "xx"
      ]
    },
    {
      "id": "node_014",
      "content": "Afatinib (preferred)",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [
        "node_017"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_015",
      "content": "Osimertinib (preferred)",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [
        "node_019"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_016",
      "content": "Dacomitinib or Erlotinib or Gefitinib",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [
        "node_021"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_017",
      "content": "Progression",
      "parent_ids": [
        "node_014"
      ],
      "children_ids": [
        "node_018"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_018",
      "content": "Subsequent Therapy (NSCL-23)",
      "parent_ids": [
        "node_017"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-23"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_019",
      "content": "Progression",
      "parent_ids": [
        "node_015"
      ],
      "children_ids": [
        "node_020"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_020",
      "content": "Subsequent Therapy (NSCL-22)",
      "parent_ids": [
        "node_019"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-22"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_021",
      "content": "Progression",
      "parent_ids": [
        "node_016"
      ],
      "children_ids": [
        "node_022"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_022",
      "content": "Subsequent Therapy (NSCL-23)",
      "parent_ids": [
        "node_021"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-23"
      ],
      "footnote_labels": []
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-24",
      "to_tree": "NSCL-23",
      "description": "Subsequent Therapy for progression on Afatinib, Dacomitinib, Erlotinib, or Gefitinib"
    },
    {
      "from_tree": "NSCL-24",
      "to_tree": "NSCL-22",
      "description": "Subsequent Therapy for progression on Osimertinib"
    },
    {
      "from_tree": "NSCL-24",
      "to_tree": "NSCL-H",
      "description": "Principles of Molecular and Biomarker Analysis"
    },
    {
      "from_tree": "NSCL-24",
      "to_tree": "NSCL-J",
      "description": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease"
    }
  ],
  "footnotes": [
    {
      "label": "nn",
      "content": "Principles of Molecular and Biomarker Analysis (NSCL-H)."
    },
    {
      "label": "rr",
      "content": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)."
    },
    {
      "label": "ss",
      "content": "For PS 0â€“4."
    },
    {
      "label": "ww",
      "content": "If systemic therapy regimen contains an immune checkpoint inhibitor, physicians should be aware of the long half-life of such drugs and data reporting adverse events when using osimertinib in combination with or following checkpoint inhibitors. The rate of side effects (pneumonitis) is higher within 3 months. Schoenfeld AJ, et al. Ann Oncol 2019;30:839-844; Oshima Y, et al. JAMA Oncol 2018;4:1112-1115; Oxnard GR, et al. Ann Oncol 2020;31:507-516; Gettinger S, et al. J Thorac Oncol 2018;13:1363-1372."
    },
    {
      "label": "xx",
      "content": "If there is a good response to current therapy, it is reasonable to continue therapy."
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "EGFR S768I, L861Q, and/or G719X MUTATIONS",
  "tree_id": "NSCL-24",
  "keywords": [
    "BRAF",
    "dabrafenib",
    "trametinib"
  ]
}
